Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Fax: 206 902 9658

Website: www.atossatherapeutics.com

Address:

107 Spring Street, Seattle, United States

ChrisGayle Oct. 5 at 4:17 AM

$ATOS

0 · Reply

jacksparo Oct. 4 at 5:42 PM

$ATOS This is back under my radar will share my plan this weekend in my email group!

1 · Reply

Bulltrader988 Oct. 4 at 4:01 PM

$ATOS great way to end the week.... Golden cross incoming 👃👀 https://finviz.com/quote.ashx?t=ATOS&ty=c&ta=1&p=d

0 · Reply

ShowMeThaMonay Oct. 4 at 3:46 PM

$ATOS excited for next week. I think we could hold $1 for compliance, but I’m hoping for more.

0 · Reply

dcajic2 Oct. 4 at 2:23 PM

$ATOS congrats it hit over $1. Maybe this time they will have the news to allow back in compliance.

0 · Reply

UltraMegaMAGA Oct. 4 at 12:54 PM

$ATOS great week here. Appears to be ready to breakout to the upside. Don’t let us down Doc Q!

0 · Reply

CelticBeast Oct. 4 at 12:34 PM

$ATOS 🙏🏻🍀https://youtube.com/shorts/nQ9m0bOh0uk?si=7AXwthEzNs2rYvb0

0 · Reply

DB187 Oct. 4 at 9:50 AM

$ATOS

0 · Reply

scrappy_trader Oct. 4 at 4:00 AM

$ATOS - Our plan is to get into compliance the natural way...Dr Quay Slow, steady and sure way to go Dr Have a feeling that Dr is in touch with some big whale investors with good news. The big whales are loading steady without any major alerts or change of SP Looking forward for an exciting week

1 · Reply

JDAAT Oct. 4 at 2:12 AM

$ATOS it will be fun if we go straight over $1.30 so all those who sold on the way down will be out of this stock

1 · Reply

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 17 days ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 8:30 AM EDT - 26 days ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 5 weeks ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 6 weeks ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 7 weeks ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 29, 2025, 7:45 AM EDT - 2 months ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 2, 2025, 8:45 AM EDT - 4 months ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 9:00 AM EDT - 4 months ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 5 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 8:45 AM EDT - 5 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 5 months ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 5 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 6 months ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 25, 2025, 10:05 AM EDT - 6 months ago

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 7 months ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:15 AM EDT - 7 months ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Feb 5, 2025, 8:00 AM EST - 8 months ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Jan 30, 2025, 8:17 AM EST - 8 months ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Jan 23, 2025, 8:15 AM EST - 9 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Dec 12, 2024, 8:15 AM EST - 10 months ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 8:15 AM EST - 10 months ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Dec 10, 2024, 9:05 AM EST - 10 months ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Dec 9, 2024, 8:15 AM EST - 10 months ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Nov 21, 2024, 8:30 AM EST - 11 months ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Nov 20, 2024, 8:30 AM EST - 11 months ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Nov 12, 2024, 8:30 AM EST - 11 months ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 8:30 AM EST - 11 months ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Nov 4, 2024, 6:30 AM EST - 11 months ago

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Oct 14, 2024, 5:08 PM EDT - 1 year ago

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Aug 21, 2024, 11:30 AM EDT - 1 year ago

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Jul 2, 2024, 4:15 PM EDT - 1 year ago

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Jun 5, 2024, 8:30 AM EDT - 1 year ago

Atossa to Present at the Sidoti Small-Cap Investor Conference

May 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

May 15, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

May 13, 2024, 8:50 AM EDT - 1 year ago

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

ChrisGayle Oct. 5 at 4:17 AM

$ATOS

0 · Reply

jacksparo Oct. 4 at 5:42 PM

$ATOS This is back under my radar will share my plan this weekend in my email group!

1 · Reply

Bulltrader988 Oct. 4 at 4:01 PM

$ATOS great way to end the week.... Golden cross incoming 👃👀 https://finviz.com/quote.ashx?t=ATOS&ty=c&ta=1&p=d

0 · Reply

ShowMeThaMonay Oct. 4 at 3:46 PM

$ATOS excited for next week. I think we could hold $1 for compliance, but I’m hoping for more.

0 · Reply

dcajic2 Oct. 4 at 2:23 PM

$ATOS congrats it hit over $1. Maybe this time they will have the news to allow back in compliance.

0 · Reply

UltraMegaMAGA Oct. 4 at 12:54 PM

$ATOS great week here. Appears to be ready to breakout to the upside. Don’t let us down Doc Q!

0 · Reply

CelticBeast Oct. 4 at 12:34 PM

$ATOS 🙏🏻🍀https://youtube.com/shorts/nQ9m0bOh0uk?si=7AXwthEzNs2rYvb0

0 · Reply

DB187 Oct. 4 at 9:50 AM

$ATOS

0 · Reply

scrappy_trader Oct. 4 at 4:00 AM

1 · Reply

JDAAT Oct. 4 at 2:12 AM

$ATOS it will be fun if we go straight over $1.30 so all those who sold on the way down will be out of this stock

1 · Reply

MAX2121 Oct. 4 at 1:50 AM

$ATOS straight pump into small cap big rotation happening now - watch this not hold because dummy quay doesn’t have his ducks in order. Under $1 next week would of been perfect time to post combo trial oh wait they fucked that up.. 11 months to pivot, fire & hire that’s it.. Prove me wrong quay I doubt he will same as all the BO nonsense

0 · Reply

scrappy_trader Oct. 4 at 12:37 AM

$ATOS - Real life stories like this from @cacai61 will highlight the good work done by the good Dr Quay Fruits of his hard and sincere efforts starting to show ... Providing The Blueprint to Solve America's Health Crisis

0 · Reply

scrappy_trader Oct. 4 at 12:10 AM

$ATOS Dr Steven Quay on Twitter Another productive day What is the $ATOS CEO reading about at the end of another productive day? How and where in the clinical program of Z-Endoxifen will measuring tumor DNA from a blood sample be most beneficial. Changing the paradigm for breast #cancer, one patient and one DNA sequence at a time. Could baseline ctDNA and methylation status predict treatment benefit in advanced breast cancer? https://oncology-central.com/could-baseline-ctdna-and-methylation-status-predict-treatment-benefit-in-advanced-breast-cancer/ https://x.com/quay_dr/status/1973966034408456397

0 · Reply

Richmonddawg Oct. 3 at 11:25 PM

$ATOS I encourage people to send positive responses and copy in Dr. Marty Makary. We finally have a FDA director that seems to care about patients.

1 · Reply

Alphajoe31 Oct. 3 at 10:40 PM

$ATOS Day 1 over $1.00!! 9 to go

0 · Reply

Bunster Oct. 3 at 10:24 PM

$ATOS $1.00

1 · Reply

Bunster Oct. 3 at 10:23 PM

$ATOS QUAY NEEDS TO PUT OUT NEWS MONDAY.!!!! ANYTHING HE HAS PRIME. Someone should e mail or tweet him to. ANYTHING DECENT pretty sure if no worries were here he would do it.

0 · Reply

Bunster Oct. 3 at 10:17 PM

$ATOS week in review october 3 2025 pps 1 DOLLAR 2ND WEEK IN A ROW WEEK BELONGS TO OUR CASEY COUNTDOWN HAS BEGUN PRIMES ODDS TO CLOSE 10 BUSINESS DAYS IN A ROW 1 DOLLAR OR MORE 20 PCT AT BEST A VERY GOOD WEEK

1 · Reply

kaaskoekje Oct. 3 at 10:11 PM

$ATOS yet his posts get around 1000 views on avg. sometimes even less. I see a message board with 64k followers. People wont work for their bags or help with the engagement. we have seen proper capitulation across the board. intereresting times ahead. price is people and people ALWAYS equals the price. always remember.

1 · Reply

kaaskoekje Oct. 3 at 10:01 PM

$ATOS positive signs and cup is forming but be carefull everybody.. because, (-.(-.(-.-).-).-) @AnnieRipley is lurking in the shadows.. i see you. imagine the scenes when she cast her spells. remember prices are people and people equals prices !! oh and say hi to kitty to me guys :)

0 · Reply

Sabren Oct. 3 at 8:20 PM

$ATOS Nine more business days until compliance.

1 · Reply

Gwsgws Oct. 3 at 8:16 PM

$ATOS quay now is the time to submit fast track to keep this momentum going and regain compliance

0 · Reply

Market Cap	130.46M
Revenue (ttm)	0.00
Net Income (ttm)	-25.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,027,700
Avg Vol	925,540
Day's Range	N/A - N/A
Shares Out	129.17M
Stochastic %K	83%
Beta	1.11
Analysts	Strong Sell
Price Target	$5.69